Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 3
2021 4
2022 6
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages.
Ackerson BK, Bruxvoort KJ, Qian L, Sy LS, Qiu S, Tubert JE, Lee GS, Ku JH, Florea A, Luo Y, Bathala R, Stern J, Choi SK, Takhar HS, Aragones M, Marks MA, Anderson EJ, Zhou CK, Sun T, Talarico CA, Tseng HF. Ackerson BK, et al. Among authors: talarico ca. Hum Vaccin Immunother. 2024 Dec 31;20(1):2335052. doi: 10.1080/21645515.2024.2335052. Epub 2024 Apr 4. Hum Vaccin Immunother. 2024. PMID: 38575149 Free PMC article.
mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States.
Tseng HF, Ackerson BK, Sy LS, Tubert JE, Luo Y, Qiu S, Lee GS, Bruxvoort KJ, Ku JH, Florea A, Takhar HS, Bathala R, Zhou CK, Esposito DB, Marks MA, Anderson EJ, Talarico CA, Qian L. Tseng HF, et al. Among authors: talarico ca. Nat Commun. 2023 Sep 20;14(1):5851. doi: 10.1038/s41467-023-41537-7. Nat Commun. 2023. PMID: 37730701 Free PMC article.
Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study.
Ku JH, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, Lee GS, Florea A, Bruxvoort KJ, Xie F, Qiu S, Chavers S, Talarico CA, Tseng HF. Ku JH, et al. Among authors: talarico ca. Vaccine. 2023 Jun 29;41(29):4212-4219. doi: 10.1016/j.vaccine.2023.06.016. Epub 2023 Jun 5. Vaccine. 2023. PMID: 37301708 Free PMC article.
Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.
Ku JH, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, Lee GS, Florea A, Bruxvoort KJ, Talarico CA, Qiu S, Tian Y, Tseng HF. Ku JH, et al. Among authors: talarico ca. Vaccine. 2023 Jun 1;41(24):3636-3646. doi: 10.1016/j.vaccine.2023.04.075. Epub 2023 May 3. Vaccine. 2023. PMID: 37173268 Free PMC article.
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
Mues KE, Kirk B, Patel DA, Gelman A, Chavers LS, Talarico CA, Esposito DB, Martin D, Mansi J, Chen X, Gatto NM, Van de Velde N. Mues KE, et al. Among authors: talarico ca. Vaccine. 2022 Nov 8;40(47):6730-6739. doi: 10.1016/j.vaccine.2022.09.025. Epub 2022 Sep 24. Vaccine. 2022. PMID: 36163093 Free PMC article.
18 results